Clinical Trials Logo
  1. Home
  2. Atopic Dermatitis (AD)
  3. NCT04159597
  4. Details
NCT04159597 Clinical Trial

Expanded Access to Upadacitinib

Atopic Dermatitis (AD) Clinical Trial

Official title:
Expanded Access to Upadacitinib

Clinical Trial Details — Status: No longer available

Administrative data
NCT number NCT04159597
Other study ID # C20-082
Secondary ID
Status No longer available
Phase
First received
Last updated

Study information
Verified date August 2021
Source AbbVie
Contact n/a
Is FDA regulated No
Health authority
Study type Expanded Access

Clinical Trial Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Recruitment information / eligibility
Status No longer available
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - The participant must not be eligible for upadacitinib clinical trial.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Upadacitinib
Upadacitinib will be administered as oral tablet.

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
AbbVie
See also
  Status Clinical Trial Phase
Completed NCT03151148 - Targeted Microbiome Transplant in Atopic Dermatitis Phase 1/Phase 2
Active, not recruiting NCT05456529 - Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis Phase 3
Completed NCT04056130 - A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects Phase 1
Recruiting NCT04173442 - Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy
Completed NCT05372653 - A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis Phase 3
Completed NCT03168113 - Atopic Dermatitis (AD) and Food Allergy N/A
Terminated NCT03389893 - Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis Phase 4
Recruiting NCT04541810 - A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Completed NCT02357940 - Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema N/A
Recruiting NCT05667623 - To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD Phase 3
Recruiting NCT05650320 - To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients With AD Phase 3
Completed NCT01979016 - Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD) Phase 2
Withdrawn NCT04666675 - A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil Phase 3
Active, not recruiting NCT05959083 - Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis